Hester Biosciences reported a sharp improvement in financial performance, with profit doubling during the latest reporting period, driven by robust demand for animal healthcare products and improved operational efficiency. The strong showing reflects the company’s growing presence in veterinary vaccines and biologics, supported by favorable market conditions and disciplined cost management. Revenue growth, coupled with margin expansion, translated into a significant bottom-line gain.